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in the development of atopic 
dermatitis
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Glucocorticoids (GCs) are potent anti‑inflammatory drugs, the secretion of which is mediated and 
controlled by the hypothalamic–pituitary–adrenal axis. However, they are also secreted de novo by 
peripheral tissues for local use. Several tissues express 11β‑hydroxysteroid dehydrogenase 1 (11β‑
HSD1), including the skin. The inactive GC cortisone is converted by 11β‑HSD1 to active GC cortisol, 
which is responsible for delayed wound healing during a systemic excess of GC. However, the role 
of 11β‑HSD1 in inflammation is unclear. We assessed whether 11β‑HSD1 affects the development 
of atopic dermatitis (AD) in vitro and in vivo. The expression of 11β‑HSD1 in the epidermis of AD 
lesions was higher than that in the epidermis of healthy controls. Knockdown of 11β‑HSD1 in human 
epidermal keratinocytes increased the production of thymic stromal lymphopoietin. In an oxazolone‑
induced mouse model of AD, localized inhibition of 11β‑HSD1 aggravated the development of AD 
and increased serum cytokine levels associated with AD. Mice with whole‑body knockout (KO) of 
11β‑HSD1 developed significantly worse AD upon induction by oxazolone. We propose that 11β‑HSD1 
is a major factor affecting AD pathophysiology via suppression of atopic inflammation due to the 
modulation of active GC in the skin.
Cortisol is an endogenous glucocorticoid (GC) in humans, whose release is stimulated by the activation of the 
hypothalamic–pituitary–adrenal (HPA) axis by various  stressors1. Exogenous GCs have been used as a potent 
anti-inflammatory drug for chronic inflammatory diseases, including atopic dermatitis (AD)2,3. The main anti-
inflammatory mechanism of GCs is the suppression of inflammatory gene transcription factors such as nuclear 
factor-kappa B (NF-κB) and activator protein-14.
Apart from systemic GC production elicited by the HPA axis, extra-adrenal GCs are synthesized de novo in 
various tissues, including the brain, colon, heart, lung, thymus, and  skin5–9. Epidermal and follicular keratino-
cytes, melanocytes, and dermal fibroblasts in the skin have glucocorticosteroidogenic  activity5,6,10–13.
11β-Hydroxysteroid dehydrogenases (11β-HSDs) regulate the peripheral availability of GCs. There are two 
isoforms of 11β-HSD: 11β-HSD1 converts inactive cortisone into  cortisol14,15, whereas 11β-HSD2 inactivates 
cortisol to  cortisone16,17. Epidermal keratinocytes, dermal fibroblasts, sebocytes, and sweat gland cells in the 
skin, and the outer root sheath cells of hair follicles express 11β-HSD17,18–20, and this expression is increased by 
ultraviolet (UV) B and UVC but not UVA  irradiation17,21. Increased 11β-HSD1 expression leads to increased 
availability of local GCs and increased suppression of inflammatory responses in  keratinocytes22. The expression 
of 11β-HSD1 mRNA was reportedly higher in human dermal fibroblasts (HDFs) obtained from a donor-matched 
photo-exposed outer upper arm than in HDFs obtained from the photo-protected inner upper  arm19. The expres-
sion and activity of 11β-HSD1 were elevated in biopsies of photo-exposed skin (outer lower arm) compared to 
those in biopsies of donor-matched photo-protected skin (inner upper arm) in vivo23. Inflammation in response 
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to hapten-induced dermatitis was exacerbated and the response to topical 11-dehydrocorticosterone was attenu-
ated in keratinocyte-specific 11β-HSD1 (HSD11b1) knockout (KO) mice compared with the reactions in WT 
mice. These findings confirmed that GCs exert their immunosuppressive effect through 11β-HSD124. Therefore, 
11β-HSD1 is not only involved in the cutaneous side effects caused by excess GCs but also plays a key role in 
local anti-inflammatory activity in keratinocytes.
AD is one of the most common inflammatory diseases of the skin. It is characterized by severe pruritus and 
its multifactorial pathogenesis involves a complex combination of epidermal barrier defects, T helper cell type 2 
(Th2)-skewed inflammation, and neuroendocrinal  dysregulation14,25–28. The involvement of GCs in inflammatory 
skin diseases such as AD has been proposed recently. Several studies have described that patients with AD show 
a blunted response to psychological stress with lower cortisol production compared with normal  controls29–31. In 
mice, the absence of GC receptors in the epidermis results in skin barrier defects and increased susceptibility to 
cutaneous  inflammation32. The role of 11β-HSD1 in AD has not been studied yet. However, evidence from recent 
studies supports the notions that 11β-HSD1 is involved in inflammatory cytokine expression in keratinocytes and 
that it plays an important role in AD exacerbation by modulating local GC  availability14. The expression of thymic 
stromal lymphopoietin (TSLP) is significantly increased in the epidermis of keratinocyte-specific Hsd11b1 KO 
compared to that in WT  mice33. Moreover, GCs suppress the upregulation of TSLP in normal human epidermal 
keratinocytes (NHEK) transfected with 11β-HSD1 small interfering RNA (siRNA). Thus, endogenous GCs 
activated by the homeostatic activation of 11β-HSD1 might regulate TSLP  production33.
In this study, we aimed to determine the impact of regulation of endogenous GCs by 11β-HSD1 on the 
development of AD in vitro and in vivo.
Results
Knockdown of 11β‑HSD1 by siRNA transfection increases TSLP production in NHEKs. After 
6 and 24  h of poly I:C and IL-4 treatment, the mRNA expression level of 11β-HSD1 tended to decrease in 
siRNA-transfected NHEKs (Fig.  1a). Moreover, the cortisol concentration in the culture medium of siRNA-
transfected cells was significantly lower after 6 h of treatment (Fig. 1b). Therefore, 11β-HSD1 siRNA transfection 
knocked down 11β-HSD1 expression and 11β-HSD1 was responsible for the regulation of cortisol production. 
Both 6 h and 24 h after incubation, stimulation of TSLP production by polyinosinic:polycytidylic acid (poly I:C) 
and interleukin-4 (IL-4)levels were higher in siRNA-transfected cells (Fig. 1c). UVB irradiation induced TSLP 
expression in human keratinocytes via stabilization of hypoxia-inducible factor-1α (HIF-1α)34. The expression 
of TSLP mRNA was increased in siRNA-transfected NHEKs, and the difference was significant at 100 mJ/cm2 
UVB (Fig. 1d). TSLP levels produced by siRNA-transfected cells were significantly higher than those produced 
by the control cells after irradiation with 0, 20, and 50 mJ/cm2 UVB (Fig. 1e).
Figure 1.  Effect of 11β-HSD1 knockdown on TSLP production in NHEK cells. (a) We transfected NHEK 
with either 11β-HSD1 siRNA or negative siRNA then mRNA expression of 11β-HSD1 was quantified by 
qPCR after six and 24 h incubations with poly I:C and IL-4. (b) Cortisol in culture medium measured after 
six-hour incubation with poly I:C and IL-4. (c) Amount of TSLP in culture media measured after six and 
24 h incubations with poly I:C and IL-4. (d) mRNA expression of TSLP quantified by qPCR after irradiation 
with 0, 20, 50, 100 mJ/cm2 UVB. (e) Amount of TSLP measured after irradiation with 0, 20 and 50 mJ/cm2 
UVB (*p < 0.05, ** p < 0.005). Data are presented as means ± standard deviation. IL-4, interleukin-4; poly I:C, 
polyinosinic:polycytidylic acid; siRNA, small interfering RNA; UVB, ultraviolet B.
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Topical application of selective 11β‑HSD1 inhibitor aggravates phenotypes inoxa-
zolone‑treated mice. Oxazolone (Ox)-treated mice developed typical AD lesions. Mice treated topically 
with 11β-HSD1 inhibitor displayed worse eczema lesions than the vehicle-treated group (Fig. 2a). The eczema 
score of the 11β-HSD1 inhibitor-treated group was significantly higher than that of the vehicle-treated group 
(Fig. 2b). Transepidermal water loss (TEWL) of both Ox-AD mouse groups was significantly increased com-
pared to that of the control group. The 11β-HSD1 inhibitor-treated group displayed a higher (but not statisti-
cally significant) TEWL than the vehicle-treated group. SC hydration of Ox-treated mice was significantly lower 
than that of control mice, but there was no difference between the vehicle- and the 11β-HSD1 inhibitor-treated 
groups (Fig. 2c).
Serum inflammatory cytokines tend to increase in Ox‑AD mice. We measured the levels of vari-
ous inflammatory cytokines in mouse sera using ELISA (Fig. 3). Tumor necrosis factor-alpha (TNFα) level was 
increased in the Ox-AD group compared to that in the control group, but there was no difference between the 
11β-HSD1 inhibitor-treated Ox-AD group and the vehicle-treated Ox-AD group. Serum IL-10 levels of the 
Ox-AD groups were higher than those of the control mice, and mice treated with 11β-HSD1 inhibitor showed 
higher serum IL-10 levels than mice from the vehicle group. Serum levels of IL-4 and IL-5 Th2 cytokines tended 
to be higher in Ox-AD mice. However, no significant difference was evident between the 11β-HSD1 inhibitor-
treated and the vehicle-treated groups.
Th2 cells are increased in the skin of mice treated with 11β‑HSD1 inhibitor. We compared the 
percentage of regulatory T (Treg) cells that expressed foxp3 and CD25 among CD4-gated cells, and the percent-
age of Th2 cells that expressed IL-4 among CD3 and CD4-gated cells. The percentages of Treg cells and Th2 
cells among splenic cells did not significantly differ between mice treated with the 11β-HSD1 inhibitor and the 
vehicle. The percentage of Th2 cells in skin cells tended to be higher in the 11β-HSD1 inhibitor-treated mouse 
group, although not significantly. Skin Treg cells did not show any significant difference between the two groups 
(Supplementary Fig. 1).
Figure 2.  Effect of topical selective 11β-HSD1 inhibitor on oxazolone-evoked AD. (a) Gross photograph of 
control (n = 5), and Ox-induced female hairless (hr/hr) mice with topically applied vehicle (n = 7) and 11β-HSD1 
inhibitor (n = 7) taken before sacrifice (at 26 days). (b) Eczema scores of Ox-induced mice treated with 11β-
HSD1 inhibitor and vehicle at challenges 5–10. (c) TEWL and SC hydration in control and Ox-induced mice 
with vehicle and 11β-HSD1 inhibitor before sacrifice (at 26 days) (*p < 0.05, **p < 0.005). Data are presented 
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Figure 3.  Serum inflammatory cytokines tend to be elevated in Ox-AD mice. Serum TNF-α, IL-10, IL-4 
and IL-5 values determined by ELISA in control and Ox-induced mice with vehicle and 11β-HSD1 inhibitor 
(*p < 0.05). Data are presented as means ± standard deviation. HSD1 inh 11β-HSD1 inhibitor, Ox oxazolone.
Figure 4.  Epidermal 11β-HSD1 expression is significantly increased in Ox-AD mice. (a) Immunohistochemical 
staining and (b) staining intensity of 11β-HSD1 in the epidermis of control and Ox-AD mice (scale 
bar = 100 μm). Staining intensity of 11β-HSD1 in the epidermis was graded as 0 (none), 1 (very weak), 2 (weak), 
3 (moderate), 4 (strong), and 5 (very strong). Mean scores were compared between controls and Ox-AD mice 
(*p < 0.05). Data are presented as means ± standard deviation. Ox-AD oxazolone-induced atopic dermatitis.
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Epidermal 11β‑HSD1 expression is significantly increased in Ox‑AD mice. The staining intensity 
of 11β-HSD1 was significantly higher in the epidermis of Ox-AD mice than in control mice (Fig. 4a). Semi-
quantitative IHC scores (from 0 to 5) of Ox-AD mice were also significantly higher than control mice (p = 0.023; 
Fig. 4b).
Oxazolone worsened eczema in HSD11B1 KO mice compared to that in WT mice. Skin lesions 
were more severe after 10 Ox challenges in mice with global HSD11B1 KO than in WT mice (Fig. 5a). The patho-
logical features of both Ox-treated groups were characterized by marked epidermal hyperplasia with spongiosis, 
cellular infiltrates of mononuclear and polymorphonuclear cells, and dermal thickening, which is characteristic 
of AD (Fig. 5b). However, atopic inflammation was worse in KO mice due to the epidermis and dermis being 
significantly thickened. Histological scores for dermal inflammation and collagen density were also significantly 
higher in the KO than in the WT mice (Fig. 5c). Eczema scores were significantly higher in the HSD11B1 KO 
mice (Fig. 5d). The TEWL and pH of the SC were significantly higher in the HSD11B1 KO than in the WT mice, 
but SC hydration did not significantly differ between the groups (Fig. 5e). Corticosterone levels were higher in 
the KO than in the WT mice, although the difference was not significant (Fig. 5f).
Inflammatory cytokine expression is increased in skin of HSD11B1 KO mice. The mRNA 
expression levels of TSLP, IL-4, and IL-10, which are crucial cytokines in AD, were increased in the epidermis 
of KO mice compared to the expression levels in WT mice. IL-4 and IL-10 levels were significantly higher in the 
KO group (p = 0.017 and 0.013, respectively). The mRNA expression of interferon-gamma (IFN-γ), an immu-
nomodulatory cytokine, was also increased in KO mice, but the difference did not reach statistical significance 
(Fig. 6).
Epidermal 11β‑HSD1 expression is decreased in the lesional skin of patients with AD. The 
staining intensity of 11β-HSD1 was significantly lower in the epidermis of skin lesions of patients with AD than 
in non-lesional skin and healthy control skin (Fig. 7a). Semi-quantitative IHC scores showed no significant dif-
ference between control and non-lesional skin of patients with AD. Lesions of patients with AD tended to have 
lower staining intensity than skin of healthy controls and non-lesions of patients with AD, but failed to show 
statistical significance (Fig. 7b).
Figure 5.  Oxazolone-induced atopic dermatitis in HSD11B1 KO and WT mice. (a) Gross photographs of 
skin lesions in global HSD11B1 KO mice with AD induced by Ox and WT mice (n = 8/group) taken before 
sacrifice (at 26 days). (b) Macroscopic appearance of skin sections of dorsal lesional surface. Scale bar, 10 µm. 
(c) Histological scores for dermal inflammation and density measured as epidermal and dermal thickness. 
(d) Eczema scores for HSD11B1 KO and WT mice at challenges 5–10. (e) TEWL, SC pH and SC hydration 
measured before sacrifice (at 26th day). (f) Corticosterone levels in epidermis of KO and WT mice measured 
by ELISA (*p < 0.05, ** p < 0.005). Data are presented as means ± standard deviation. KO knock out, SC stratum 
corneum, TEWL transepidermal water loss.
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Figure 6.  Increased inflammatory cytokine expression in skin of HSD11B1 KO mice. Expression of TSLP, 
IFN-γ, IL-4 and IL-10 in epidermis of HSD11B1 KO and WT mice analyzed using qPCR (*p < 0.05). Data are 
presented as means ± standard deviation. KO, knockout; WT, wild type.
Figure 7.  Epidermal 11β-HSD1 expression in the stratum corneum decreased in the lesional skin of patients 
with AD. (a) Immunohistochemical staining and (b) staining intensity of 11β-HSD1 in epidermis of lesions and 
non-lesions of four patients with AD and four individuals without AD (scale bar = 100 μm). Staining intensity 
of 11β-HSD1 in the epidermis was graded as 0 (none), 1 (very weak), 2 (weak), 3 (moderate), 4 (strong), and 5 
(very strong). Mean scores were compared between controls, lesions, and non-lesions of patients with AD. Data 
are presented as means ± standard deviation. AD atopic dermatitis.
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Discussion
Human skin functions as an independent steroidogenic organ that maintains homeostasis against external 
 stress35,36. The role of 11β-HSD1 in inflammation has been studied. Inhibition of 11β-HSD1 in murine mac-
rophages treated with lipopolysaccharide suppresses pro-inflammatory cytokine  expression37. Moreover, inhibit-
ing 11β-HSD1 reduces the TNFα-induced expression of IL-6, whereas 11β-HSD1 overexpression further aug-
ments IL-6  expression38. Knockdown of 11β-HSD1 in NHEK by siRNA transfection abrogates the induction 
of IL-6 and IL-8 by IL-1β and TNFα4. These results suggest that 11β-HSD1 expression is needed to produce 
inflammatory cytokines.
On the contrary, 11β-HSD1 plays a protective role in models of inflammation in vivo. 11β-HSD1-deficient 
K/B × N serum-induced arthritis model mice showed earlier onset and slower resolution of  inflammation39. 
When contact dermatitis was induced in mice using hapten, keratinocyte-specific 11β-HSD1 KO mice showed 
enhanced inflammation compared to WT  mice24. These inconsistent results may reflect the complexity of sys-
temic and local GC production affected by a de novo pathway and 11β-HSD1 action.
Two distinct 11β-HSDs and four distinct 17β-HSDs are known in mammals. The preference of the two 
11β-HSDs and four 17β-HSDs for catalyzing oxidation or reduction of substrates has physiological benefits. 
According to Baker et al., the selective expression of different enzymes at different times in different tissues can 
control the concentration of active GCs or estrogens and androgens, providing a mechanism for regulating the 
actions of these hormones and maintaining normal  physiology40. Phylogeny suggests that evolution of these 
enzymes from ancestor HSD may have occurred during the transition of vertebrates from ocean to land due to 
selective pressures from the colonization of land. 11β-HSD1 is most abundant in the liver and adipose tissue, 
but it is also widely expressed in the epidermis and dermis. In contrast, 11β-HSD2 shows lower expression in the 
 skin41. As the skin is the outermost organ of the body and is in constant contact with the environment, inflam-
mation frequently occurs and keratinocytes differentiate repeatedly. Due to the nature of the skin, 11β-HSD1 
was highly conserved in the skin through human evolution and served as an “endogenous pharmacy.” However, 
complications, such as skin aging and inhibition of wound healing, appear when the enzyme is overexpressed 
as a result of UV exposure and endogenous aging.
We found that 11β-HSD1 expression was increased in the epidermis of flaky tail mouse models of congenital 
AD that spontaneously develop AD lesions. Sensitizing the skin of flaky tail mice with a mite allergen further 
increased 11β-HSD1 expression (data not published). Thus, we concluded that 11β-HSD1 action is important 
for dampening inflammation in the skin through GC activation, and that the reduced activity of this enzyme 
might promote the development of inflammatory skin diseases, including AD. Therefore, we speculated that 
inhibition of 11β-HSD1 decreases the levels of active cortisol in the skin and aggravates AD severity in the mouse 
model of Ox-induced AD.
A study to determine whether 11β-HSD1 knockdown in keratinocytes affects the production of TSLP that 
functions as a master switch for the Th2 immune response in  AD42 found significantly higher TSLP production 
after stimulation with poly I:C and IL-4 in siRNA-transfected NHEK. These results agree with later  findings33. 
Irradiation with UVB induces TSLP expression in human  keratinocytes34. The present study found that siRNA 
transfection increased the amount of TSLP induced by UVB irradiation. Although we found that siRNA transfec-
tion almost completely inhibited 11β-HSD1 expression, 11β-HSD1 KO only partly inhibited cortisol production 
by keratinocytes (Fig. 2b). This is because the skin can synthesize extra-adrenal glucocorticoid. Slominski et al. 
found that skin and skin cells express the genes and proteins required to activate the cytochrome P450scc system, 
indicating that skin can metabolize glucocorticoid from  cholesterol43.
The local inhibition of 11β-HSD1 in the skin of Ox-AD hairless mice should aggravate the severity of atopic 
inflammation by suppressing GC activation. Eczema lesions, developed in the skin of hairless mice after four 
applications of Ox and worsened according to eczema scores in mice that were topically treated with an 11β-
HSD1 inhibitor. The skin permeability barrier function, indicated by basal TEWL and SC hydration, was dis-
rupted in Ox-AD mice compared with that in control mice, but those treated with vehicle and with the 11β-HSD1 
inhibitor did not significantly differ.
There are no reported protocols regarding the concentration of topical 11β-HSD1 inhibitor (385581). How-
ever, in a report published in 2014, Terao and colleagues dissolved 385581 in DMSO (10 μM) for subcutaneous 
injection daily for 2 days44. They also used 385581 (50 μM) dissolved in acetone:olive oil (1:1) applied topically 
every day for 5 days and 385581 dissolved in PBS (10 μM) to apply to skin wounds in a report published in 
 201118. Neither report indicated a specific reference or consensus for their concentration choices. In our study, 
we chose a concentration of 100 μM of 385581 dissolved in DMSO, which is easily accessible as a vehicle in the 
laboratory, and 100 μL was applied to the skin twice a day. The results of our experiment were as expected from 
our hypothesis, suggesting that this concentration was effective.
Serum levels of inflammatory cytokines were higher in Ox-AD mice than in control mice, and even more 
so in mice with localized 11β-HSD1-inhibition, although the differences did not reach statistical significance. 
IL-10 induces Th2 but also has anti-inflammatory effects, and is increased in skin lesions in patients with  AD45. 
Decreased IL-10 levels are associated with AD  flares46. IL-10 forms heterodimers and binds to the IL-10 receptor 
to activate the Janus kinase-signal transducer and activator of transcription signaling pathway, notably Janus 
kinase 1, tyrosine kinase 2, and signal transducer and activator of transcription 3 and  147. Its anti-inflammatory 
effects are mediated by inhibition of IFN-γ and IL-2 production by Th1 cells and inhibition of IL-4 and IL-5 
production by Th2 cells through interference with B7/CD28-dependent  signals48. The present study showed 
increased IL-10 levels in Ox-AD mice and higher mean IL-10 levels in mice that were topically treated with 
11β-HSD1 inhibitor compared to vehicle-treated mice; however, the difference was not statistically significant. 
These results implied that although locally inhibited GC activation worsened eczema, it was insufficient to cause 
systemic effects. On the other hand, compared to WT mice, HSD11B1 KO mice had significantly higher levels of 
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IL-10 in the skin. It would have been useful if genes or proteins associated with IL-10 were evaluated to determine 
the consequences of increased IL-10 on AD inflammation, but this could not be done due to a lack of samples.
Fluorescence-activated cell sorting (FACS) showed that the number of Th2 cells tended to increase in the skin 
of mice with localized 11β-HSD1 inhibition. However, the numbers of foxp3 + Treg and splenic cells in skin did 
not significantly differ. Treg cells are immuneregulators that diminish excessive immune responses, including 
those of harmful Th2  cell49. Because splenic cells represent systemic inflammation, topical 11β-HSD1 inhibition 
might have weakened Th2 inflammation exclusively in the skin by blocking GC conversion to its active form. 
This may share meaning with the cytokine analysis in the skin, although we could not measure cytokine levels 
in the skin of mice due to a lack of skin samples.
We assessed the impact of systemic 11β-HSD1 inhibition on the emergence of AD lesions in global HSD11B1 KO 
mice in vivo. Others have validated the role of 11β-HSD1 in KO mice. One study describes the phenotypes of mice 
with targeted 11β-HSD1 and 11β-HSD2 deletions. Serum corticosterone is hypersecreted and the adrenal glands are 
hypertrophied in HSD11B1 KO mice due to the absence of normal negative feedback and failure of the HPA axis to 
 compensate50. Fasting glucose levels were similar between the KO and WT mice, but the responses of gluconeogenic 
enzymes were attenuated after starvation in the KO mice and they were resistant to hyperglycemia when stressed. 
Others have noted a discrepancy between secretion of local and systemic corticosterone in these KO mice, which 
has hindered clarification of the role of 11β-HSD1 in dermal collagen  metabolism44. In contrast, one study found 
that HPA axis abnormalities in response to 11β-HSD1 are strain-dependent51, because congenic HSD1 KO mice on 
a C57Bl/6J background have normal basal plasma corticosterone and ACTH concentrations, in contrast to 129/MF1 
mice that are null for 11β-HSD1. Others have found that age-induced dermal atrophy is reversed and that the col-
lagen biosynthesis gene is expressed in HSD11B1 KO  mice23. Results obtained with keratinocyte-specific HSD11B1 
KO mice were consistent with the notion that corticosterone activation by 11β-HSD1 in keratinocytes represses 
local  inflammation22,24; this rules out the impact of a compensatory increase in serum corticosterone in global KO 
mice. Moreover, serum corticosterone concentrations did not differ between WT and keratinocyte-specific KO mice.
We confirmed that the systemic inhibition of 11β-HSD1 significantly worsened AD evoked by Ox. These 
results were also supported by the histological features of a thickened epidermis and dermis, as well as higher 
scores for dermal inflammation and density in KO mice. Skin barrier permeability functions were also decreased 
in the KO mice. TEWL and SC pH was higher in KO mice. Elevated SC pH increases activity of kallikreins, which 
contributes to over degradation of corneodesmosomes followed by weakening of SC integrity and cohesion. It 
also impairs lipid processing and disrupts the permeability barrier of the epidermis. Therefore, antigen uptake 
increases through the disrupted skin barrier, which activates Langerhans cells, and then PAR-2 and TSLP are 
increased in the blood as well as the skin, contributing to AD-like  inflammation52,53.
The principle cytokines involved in the pathogenesis of AD were increased in the epidermis of KO mice 
compared with WT mice. In contrast, corticosterone levels tended to be higher in the epidermis of KO mice. This 
might have been due to excessive corticosterone production by the central HPA axis or local production by the 
peripheral HPA axis in the skin to compensate for insufficient peripheral corticosterone. We investigated whether 
HSD11B1 KO mice have functional circadian rhythms by measuring serum corticosterone (n = 1 per time point). 
Corticosterone values peaked at 1 the 5:00 and 18:30 hours and the reached at rough at 09:00 and 21:00 hours. 
The overall trend was similar to previous findings but differed somewhat in terms of peak timing (Supplementary 
Fig. 3). The range of serum corticosterone values was similar to that of previous  findings54. We collected blood 
and skin samples at 09:00 hours which could be a disadvantage, but four investigators simultaneously sampled the 
mice, therefore it could be assumed that results were not influenced by the difference in time of sample collection.
The intensity of IHC staining for 11β-HSD1 in the epidermis showed the opposite results between murine AD 
models and human subjects. AD mice induced with Ox application exhibited an increased concentration of 11β-
HSD1 in the epidermis compared to the controls. On the contrary, lesional skin of patients with AD showed the 
lowest 11β-HSD1 intensity compared to non-lesions of patients with AD and healthy control subjects, although 
the p-value did not reach statistical significance. Our results are similar to those of Terao et al., who reported that 
the expression of 11β-HSD1 increased in the epidermis of murine models after exposure of the models to 0.2% 
 Oxa24; however, the expression of 11β-HSD1 is significantly decreased in the epidermis of patients with  AD33. 
The discrepancy between murine and human subjects has yet to be investigated, but we propose the possibility 
that although short-term inflammation enhances 11β-HSD1 levels to suppress the inflammation, consistent long-
term production of Th2 type cytokines may exert an inhibitory effect on the activity of 11β-HSD1 in the skin.
Our study results in vitro and in vivo confirmed that 11β-HSD1 plays a role in the development of AD. As 
a pathogenic mechanism of AD, disruption of the skin permeability barrier leads to the increase of various 
inflammatory cytokine, evoking chronic inflammation in the  skin14,55. In addition, activation of 11β-HSD1 in 
the skin protects against atopic inflammation by increasing the local availability of active GC, which are potent 
immuno-suppressants. Although control of systemic cortisol/corticosterone by the HPA axis is important for 
anti-inflammation, the de novo pathway and local control by 11β-HSD1 are also important in the skin. We have 
identified that inhibition of 11β-HSD1 activity alone aggravates AD inflammation irrespective of serum CS levels, 
and also verified that 11β-HSD1 activity is decreased in the skin of AD patients. In conclusion, insufficient 11β-
HSD1 production or activity could function in the intricate pathophysiology of AD. If so, using methods that 
control local activity of 11β-HSD1 in the skin to treat atopic dermatitis could provide further insight into novel 
therapeutic approaches that prevent side effects from steroids that control systemic corticosterone.
Methods
Studies in vitro. Transfection with siRNA. We transfected NHEKs with 50 nM 11β-HSD1 siRNA or con-
trol siRNA (Bioneer, Daejeon, Korea) using a mixture of Opti-MEM and Lipofectamine RNAiMAX reagent 
(Invitrogen, Carlsbad, CA, USA). The culture medium was replaced after six hours and the cells were used for 
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experiments at 48 h after transfection. Detailed information about siRNA transfection, poly I:C and IL-4 treat-
ment, UVB irradiation, qPCR, and ELISA is provided in the online Supplementary Materials and Methods.
Studies in vivo. Mouse experiments. The Institutional Animal Care and Use Committee at Yonsei Univer-
sity Wonju College of Medicine approved all animal procedures (YWC-150303-1). All animal handling proce-
dures and human involvement methods were carried out in accordance with relevant guidelines and regulations. 
Eight-week-old female hairless mice (hr/hr) were obtained from OrientBio (Seongnam, Korea). Oxazolone was 
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). The selective 11β-HSD1 inhibitor, 385581 (Merck & 
Co., Kenilworth, NJ, USA), was dissolved in dimethyl sulfoxide (DMSO; 100 μM) vehicle for topical application.
The control group consisted of five mice, and the Ox-treated groups consisted of seven mice, each. Atopic 
dermatitis-like lesions were induced by the topical application of Ox (Supplementary Fig. 2). The mice were 
sensitized with a single application of 1% Ox (60 μL). One week later, 0.1% Ox (60 μL) was topically applied 
every other day for 20 days. We concurrently applied 100 μL of 385581 twice daily to both sides of half of the 
mice (seven) with induced AD and DMSO vehicle to the other half (seven mice). The control group was similarly 
treated with acetone. Eczema was scored at every challenge, and gross AD lesions were photographed on the 
day the mice were sacrificed. The eczema score was defined as the average of individual scores for symptoms of 
erythema, edema, and lichenification, and graded as 0 (none), 1 (mild), 2 (moderate) or 3 (severe)56. Excoria-
tion was excluded, as it is difficult to evaluate in mice. We measured TEWL on the dorsal skin of mice using a 
TEWA meter (Courage + Khazaka Electronics GmbH., Köln, Germany) and SC hydration using a Corneometer 
(Courage + Khazaka) before sacrifice (at 26 days). Dorsal skin, spleen and blood samples were collected from 
the mice post mortem.
Histological analysis. Detailed descriptions are provided in the Supplementary Materials and Methods, which 
are available online.
Enzyme-linked immunosorbent assay (ELISA). Detailed descriptions are provided in the online Supplementary 
Materials and Methods.
Flow cytometry. Detailed descriptions are provided in the online Supplementary Materials and Methods.
HSD11B1 KO mice. Mouse embryos with global HSD11B1 KO were supplied by Professor Gareth G. Lavery of 
the Molecular Metabolism Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experi-
mental Medicine, Institute of Biomedical Research University of Birmingham, UK. We generated and injected 
HSD11B1 KO gene clones into C57BL/6 blastocysts as  described57. The embryos were transferred into pseudo-
pregnant C57BL/6 female mice and heterozygous mice were generated. Germline transmission of the KO allele 
was confirmed by PCR genotyping, then homozygous HSD11B1 KO mice were obtained after several breeding 
cycles Details of the genotyping are provided in the online Supplementary Materials and Methods.
Experiments using HSD11B1 KO mice. Oxazolone was applied as described above to induce AD-like lesions in 
11- to 20-week-old KO and WT mice (n = 8 each). One day after the  10th Ox challenge, eczema was scored and 
photographed in each mouse, then TEWL, SC hydration, and SC pH were measured before sacrifice at 26 days. 
Dorsal and ear skin, and blood samples were taken post mortem.
Histological analysis. Detailed descriptions are provided in the online Supplementary Materials and Methods.
Quantitative polymerase chain reaction (qPCR). A detailed description of the qPCR is provided in the online 
Supplementary Materials and Methods.
Studies on human samples. Detailed descriptions are provided in Supplementary Materials and Methods, 
which are available online.
Statistical analyses. Data in graphs are expressed as means ± standard deviation. Differences between 
groups were analyzed by Student t tests using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Differ-
ences between treated groups at each time point were determined using two-way analysis of variance (ANOVA) 
followed by Bonferroni-Dunn tests. Mann–Whitney test was used to compare the staining intensities of human 
skin samples. Values with p < 0.05 were considered statistically significant.
Data availability
No datasets were generated or analyzed during the current study.
Received: 31 July 2020; Accepted: 6 November 2020
10
Vol:.(1234567890)
Scientific Reports |        (2020) 10:20237  | https://doi.org/10.1038/s41598-020-77281-x
www.nature.com/scientificreports/
References
 1. Nicolaides, N. C., Charmandari, E., Chrousos, G. P. & Kino, T. Circadian endocrine rhythms: the hypothalamic–pituitary–adrenal 
axis and its actions. Ann. N. Y. Acad. Sci. 1318, 71–80. https ://doi.org/10.1111/nyas.12464 (2014).
 2. Adcock, I. M. & Caramori, G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol. Cell Biol. 
79, 376–384. https ://doi.org/10.1046/j.1440-1711.2001.01025 .x (2001).
 3. Stojadinovic, O. et al. Novel genomic effects of glucocorticoids in epidermal keratinocytes: inhibition of apoptosis, interferon-
gamma pathway, and wound healing along with promotion of terminal differentiation. J. Biol. Chem. 282, 4021–4034. https ://doi.
org/10.1074/jbc.M6062 62200 (2007).
 4. Itoi, S., Terao, M., Murota, H. & Katayama, I. 11beta-Hydroxysteroid dehydrogenase 1 contributes to the pro-inflammatory response 
of keratinocytes. Biochem. Biophys. Res. Commun. 440, 265–270. https ://doi.org/10.1016/j.bbrc.2013.09.065 (2013).
 5. Skobowiat, C., Dowdy, J. C., Sayre, R. M., Tuckey, R. C. & Slominski, A. Cutaneous hypothalamic–pituitary–adrenal axis homolog: 
regulation by ultraviolet radiation. Am. J. Physiol. Endocrinol. Metab. 301, E484–E493. https ://doi.org/10.1152/ajpen do.00217 .2011 
(2011).
 6. Hannen, R. F. et al. Steroid synthesis by primary human keratinocytes; implications for skin disease. Biochem. Biophys. Res. Com-
mun. 404, 62–67. https ://doi.org/10.1016/j.bbrc.2010.11.059 (2011).
 7. Cirillo, N. & Prime, S. S. Keratinocytes synthesize and activate cortisol. J. Cell Biochem. 112, 1499–1505. https ://doi.org/10.1002/
jcb.23081 (2011).
 8. Slominski, A. & Wortsman, J. Neuroendocrinology of the skin. Endocr. Rev. 21, 457–487. https ://doi.org/10.1210/edrv.21.5.0410 
(2000).
 9. Taves, M. D., Gomez-Sanchez, C. E. & Soma, K. K. Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local 
synthesis, regulation, and function. Am. J. Physiol. Endocrinol. Metab. 301, E11–E24. https ://doi.org/10.1152/ajpen do.00100 .2011 
(2011).
 10. Slominski, A. T. et al. Cytochromes p450 and skin cancer: role of local endocrine pathways. Anticancer Agents Med. Chem. 14, 
77–96 (2014).
 11. Slominski, A. T. et al. Sensing the environment: regulation of local and global homeostasis by the skin’s neuroendocrine system. 
Adv. Anat. Embryol. Cell Biol. 212, v, vii, 1–115 (2012).
 12. Slominski, A. et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am. J. Physiol. Endocrinol. 
Metab. 288, E701–E706. https ://doi.org/10.1152/ajpen do.00519 .2004 (2005).
 13. Slominski, A., Zbytek, B., Szczesniewski, A. & Wortsman, J. Cultured human dermal fibroblasts do produce cortisol. J. Investig. 
Dermatol. 126, 1177–1178. https ://doi.org/10.1038/sj.jid.57002 04 (2006).
 14. Lin, T. K., Zhong, L. & Santiago, J. L. Association between stress and the HPA axis in the atopic dermatitis. Int. J. Mol. Sci. https ://
doi.org/10.3390/ijms1 81021 31 (2017).
 15. Cooper, M. S. & Stewart, P. M. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal 
axis, metabolic syndrome, and inflammation. J. Clin. Endocrinol. Metab. 94, 4645–4654. https ://doi.org/10.1210/jc.2009-1412 
(2009).
 16. Vukelic, S. et al. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury. J. Biol. Chem. 286, 10265–10275. https ://doi.
org/10.1074/jbc.M110.18826 8 (2011).
 17. Skobowiat, C., Sayre, R. M., Dowdy, J. C. & Slominski, A. T. Ultraviolet radiation regulates cortisol activity in a waveband-dependent 
manner in human skin ex vivo. Br. J. Dermatol. 168, 595–601. https ://doi.org/10.1111/bjd.12096 (2013).
 18. Terao, M. et al. 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promot-
ing tissue repair. PLoS ONE 6, e25039. https ://doi.org/10.1371/journ al.pone.00250 39 (2011).
 19. Tiganescu, A., Walker, E. A., Hardy, R. S., Mayes, A. E. & Stewart, P. M. Localization, age- and site-dependent expression, and 
regulation of 11beta-hydroxysteroid dehydrogenase type 1 in skin. J. Investig. Dermatol. 131, 30–36. https ://doi.org/10.1038/
jid.2010.257 (2011).
 20. Miller, W. L. & Auchus, R. J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. 
Endocr. Rev. 32, 81–151. https ://doi.org/10.1210/er.2010-0013 (2011).
 21. Tiganescu, A. et al. UVB induces epidermal 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo. Exp. Dermatol. 24, 
370–376. https ://doi.org/10.1111/exd.12682 (2015).
 22. Itoi-Ochi, S., Terao, M., Murota, H. & Katayama, I. Local corticosterone activation by 11beta-hydroxysteroid dehydrogenase 1 in 
keratinocytes: the role in narrow-band UVB-induced dermatitis. Dermatoendocrinology 8, e1119958. https ://doi.org/10.1080/19381 
980.2015.11199 58 (2016).
 23. Tiganescu, A. et al. 11beta-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J. 
Clin. Investig. 123, 3051–3060. https ://doi.org/10.1172/JCI64 162 (2013).
 24. Terao, M. et al. Local glucocorticoid activation by 11beta-hydroxysteroid dehydrogenase 1 in keratinocytes: the role in hapten-
induced dermatitis. Am. J. Pathol. 186, 1499–1510. https ://doi.org/10.1016/j.ajpat h.2016.01.014 (2016).
 25. Elias, P. M. & Wakefield, J. S. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clin. Rev. Allergy 
Immunol. 41, 282–295. https ://doi.org/10.1007/s1201 6-010-8231-1 (2011).
 26. Ohtsu, H. & Seike, M. Histamine and histamine receptors in allergic dermatitis. Handb. Exp. Pharmacol. 241, 333–345. https ://
doi.org/10.1007/164_2016_9 (2017).
 27. Guttman-Yassky, E. & Krueger, J. G. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. Curr. Opin. 
Immunol. 48, 68–73. https ://doi.org/10.1016/j.coi.2017.08.008 (2017).
 28. Gittler, J. K. et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and 
chronic atopic dermatitis. J. Allergy Clin. Immunol. 130, 1344–1354. https ://doi.org/10.1016/j.jaci.2012.07.012 (2012).
 29. Buske-Kirschbaum, A., Ebrecht, M. & Hellhammer, D. H. Blunted HPA axis responsiveness to stress in atopic patients is associ-
ated with the acuity and severeness of allergic inflammation. Brain Behav. Immun. 24, 1347–1353. https ://doi.org/10.1016/j.
bbi.2010.06.013 (2010).
 30. Buske-Kirschbaum, A., Geiben, A., Hollig, H., Morschhauser, E. & Hellhammer, D. Altered responsiveness of the hypothalamus-
pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic dermatitis. J. Clin. Endocrinol. 
Metab. 87, 4245–4251. https ://doi.org/10.1210/jc.2001-01087 2 (2002).
 31. Priftis, K. N., Papadimitriou, A., Nicolaidou, P. & Chrousos, G. P. The hypothalamic–pituitary–adrenal axis in asthmatic children. 
Trends Endocrinol. Metab. 19, 32–38. https ://doi.org/10.1016/j.tem.2007.10.005 (2008).
 32. Sevilla, L. M., Latorre, V., Sanchis, A. & Perez, P. Epidermal inactivation of the glucocorticoid receptor triggers skin barrier defects 
and cutaneous inflammation. J. Investig. Dermatol. 133, 361–370. https ://doi.org/10.1038/jid.2012.281 (2013).
 33. Matsumoto, A., Murota, H., Terao, M. & Katayama, I. Attenuated activation of homeostatic glucocorticoid in keratinocytes induces 
alloknesis via aberrant artemin production. J. Investig. Dermatol. 138, 1491–1500. https ://doi.org/10.1016/j.jid.2018.02.010 (2018).
 34. Jang, Y. et al. UVB induces HIF-1alpha-dependent TSLP expression via the JNK and ERK pathways. J. Investig. Dermatol. 133, 
2601–2608. https ://doi.org/10.1038/jid.2013.203 (2013).
11
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20237  | https://doi.org/10.1038/s41598-020-77281-x
www.nature.com/scientificreports/
 35. Slominski, A. et al. Steroidogenesis in the skin: implications for local immune functions. J. Steroid Biochem. Mol. Biol. 137, 107–123. 
https ://doi.org/10.1016/j.jsbmb .2013.02.006 (2013).
 36. Slominski, A. T., Manna, P. R. & Tuckey, R. C. On the role of skin in the regulation of local and systemic steroidogenic activities. 
Steroids 103, 72–88. https ://doi.org/10.1016/j.stero ids.2015.04.006 (2015).
 37. Ishii, T. et al. Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages—role of 11beta-
HSD1 in pro-inflammatory properties in macrophages. FEBS Lett. 581, 349–354. https ://doi.org/10.1016/j.febsl et.2006.11.032 
(2007).
 38. Ishii-Yonemoto, T. et al. Glucocorticoid reamplification within cells intensifies NF-kappaB and MAPK signaling and reinforces 
inflammation in activated preadipocytes. Am. J. Physiol. Endocrinol. Metab. 298, E930–E940. https ://doi.org/10.1152/ajpen do.00320 
.2009 (2010).
 39. Coutinho, A. E. et al. 11beta-Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and 
experimental arthritis in mice. Endocrinology 153, 234–240. https ://doi.org/10.1210/en.2011-1398 (2012).
 40. Baker, M. E. Unusual evolution of 11beta- and 17beta-hydroxysteroid and retinol dehydrogenases. BioEssays 18, 63–70. https ://
doi.org/10.1002/bies.95018 0112 (1996).
 41. Chapman, K., Holmes, M. & Seckl, J. 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid 
action. Physiol. Rev. 93, 1139–1206. https ://doi.org/10.1152/physr ev.00020 .2012 (2013).
 42. Cianferoni, A. & Spergel, J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev. 
Clin. Immunol. 10, 1463–1474. https ://doi.org/10.1586/17446 66X.2014.96768 4 (2014).
 43. Slominski, A. et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system 
in mammalian skin. Eur. J. Biochem. 271, 4178–4188. https ://doi.org/10.1111/j.1432-1033.2004.04356 .x (2004).
 44. Terao, M. et al. 11beta-hydroxysteroid dehydrogenase 1 specific inhibitor increased dermal collagen content and promotes fibroblast 
proliferation. PLoS ONE 9, e93051. https ://doi.org/10.1371/journ al.pone.00930 51 (2014).
 45. Ohmen, J. D. et al. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity 
reactions. J. Immunol. 154, 1956–1963 (1995).
 46. Darling, A. R. et al. IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in 
a mouse model of eczema vaccinatum. Clin. Immunol. 150, 153–160. https ://doi.org/10.1016/j.clim.2013.11.010 (2014).
 47. Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A. & Hymowitz, S. G. Regulation and functions of the IL-10 family of cytokines in 
inflammation and disease. Annu. Rev. Immunol. 29, 71–109. https ://doi.org/10.1146/annur ev-immun ol-03121 0-10131 2 (2011).
 48. Jung, B. G., Cho, S. J., Ko, J. H. & Lee, B. J. Inhibitory effects of interleukin-10 plasmid DNA on the development of atopic 
dermatitis-like skin lesions in NC/Nga mice. J. Vet. Sci. 11, 213–220. https ://doi.org/10.4142/jvs.2010.11.3.213 (2010).
 49. Ochs, H. D., Ziegler, S. F. & Torgerson, T. R. FOXP3 acts as a rheostat of the immune response. Immunol. Rev. 203, 156–164. https 
://doi.org/10.1111/j.0105-2896.2005.00231 .x (2005).
 50. Holmes, M. C., Kotelevtsev, Y., Mullins, J. J. & Seckl, J. R. Phenotypic analysis of mice bearing targeted deletions of 11beta-
hydroxysteroid dehydrogenases 1 and 2 genes. Mol. Cell Endocrinol. 171, 15–20 (2001).
 51. Carter, R. N. et al. Hypothalamic–pituitary–adrenal axis abnormalities in response to deletion of 11beta-HSD1 is strain-dependent. 
J. Neuroendocrinol. 21, 879–887. https ://doi.org/10.1111/j.1365-2826.2009.01899 .x (2009).
 52. Lee, H. J. et al. Acidification of stratum corneum prevents the progression from atopic dermatitis to respiratory allergy. Exp. 
Dermatol. 26, 66–72. https ://doi.org/10.1111/exd.13144 (2017).
 53. Hatano, Y. et al. Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis. J. Investig. Dermatol. 
129, 1824–1835. https ://doi.org/10.1038/jid.2008.444 (2009).
 54. Veniant, M. M. et al. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. 
Diabetes Obes. Metab. 11, 109–117. https ://doi.org/10.1111/j.1463-1326.2008.00911 .x (2009).
 55. Kabashima, K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. 
J. Dermatol. Sci. 70, 3–11. https ://doi.org/10.1016/j.jderm sci.2013.02.001 (2013).
 56. Yang, F. et al. Topical application of rapamycin ointment ameliorates Dermatophagoides farina body extract-induced atopic 
dermatitis in NC/Nga mice. Exp. Dermatol. 23, 568–572. https ://doi.org/10.1111/exd.12463 (2014).
 57. Semjonous, N. M. et al. Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostasis independent of 11beta-
hydroxysteroid dehydrogenase type 1. Endocrinology 152, 93–102. https ://doi.org/10.1210/en.2010-0957 (2011).
Acknowledgements
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea 
government (MEST) (NRF-2018R1A2B2005002). We are grateful to Editage (https ://www.edita ge.co.kr) for 
English language editing.
Author contributions
N.R.L.: conceptualization, formal analysis, investigation, methodology, resources, validation, visualization, writ-
ing (original draft preparation, review and editing). B.J.K.: investigation. C.H.L.: investigation. Y.B.L.: investi-
gation. S.L.: investigation, formal analysis. H.J.H.: investigation, resources, visualization. E.K.: investigation, 
resources. S.H.K.: investigation, validation. M.G.L.: resources, validation. S.E.L.: investigation, resources, vali-
dation, visualization. G.G.L.: resources. E.H.C.: conceptualization, funding acquisition, methodology, project 
administration, resources, supervision, validation, writing (review and editing).
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary information  is available for this paper at https ://doi.org/10.1038/s4159 8-020-77281 -x.
Correspondence and requests for materials should be addressed to E.H.C.
Reprints and permissions information is available at www.nature.com/reprints.




Scientific Reports |        (2020) 10:20237  | https://doi.org/10.1038/s41598-020-77281-x
www.nature.com/scientificreports/
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
